Core Viewpoint - The overall market is experiencing an upward trend, with the index approaching a rating of 3.90 stars, indicating a potential for further growth in the near future [1]. Group 1: Market Performance - All market segments, including large, medium, and small-cap stocks, have seen increases, with small-cap stocks showing the most significant gains [2]. - The CSI 1000 and 2000 indices are now considered overvalued, while the CSI 500 and low-volatility indices are quickly approaching overvaluation [2]. - Since 2018, the CSI 500 low-volatility index has nearly doubled, driven by valuation increases, profit growth, and low-volatility rebalancing [2]. Group 2: Market Phases and Trends - The current bull market is characterized by structural trends, where not all sectors rise or fall together, indicating a rotation in market styles [2]. - The A-share market has seen a significant increase of over 60% since September 2024, with three notable upward waves contributing to a total rise of approximately 74% [2][3]. - Market liquidity is a key driver of the current upward trend, influenced by the Federal Reserve's interest rate cuts and the overall global liquidity environment [3][5]. Group 3: Liquidity Factors - The Federal Reserve's anticipated interest rate cuts through 2026 are expected to maintain a favorable liquidity environment [5]. - A significant amount of deposits, approximately 30 trillion yuan, is set to mature in 2026, with a portion likely to flow into financial assets, including stocks [8][10]. - The current low interest rates on deposits are expected to redirect some funds into the stock market, although not all will enter equities [10][11]. Group 4: Corporate Earnings Growth - Corporate earnings are recovering, with a notable increase in profits for the technology sector, which is leading the market [17][18]. - Some sectors, such as consumer goods, are still experiencing declines in earnings, indicating a mixed performance across different industries [20]. - Continuous monitoring of corporate earnings growth will be essential in 2026 to gauge market expectations [21][22]. Group 5: Investment Strategy - As the market approaches a rating of 3.90 stars, the optimal phase for stock fund investments may have passed, suggesting a shift towards asset allocation and profit-taking strategies [23][24]. - The focus for 2026 should be on managing asset allocation rather than aggressive stock fund purchases [24]. Group 6: Hong Kong Market Insights - The Hong Kong market has also returned to a rating of 3.90 stars, with updated valuations provided for various indices [25]. - The valuation table for Hong Kong indices includes metrics such as P/E ratios and dividend yields, offering insights for potential investors [26].

Core Viewpoint - In 2025, despite a significant market downturn, the Hang Seng Healthcare Index maintained an annual increase of over 50%, while Hutchison China MediTech (00013) experienced an annual decline of 8.56%, underperforming the index significantly [1] Group 1: Stock Performance - Hutchison China MediTech's stock reached a peak increase of only 36.36% in 2025, with a notable decline in the second half of the year, where the stock price fell from a high of HKD 30.75 to a low of HKD 19.95, marking a maximum drop of 35.12% over four and a half months [1] - The stock showed a rebound at the beginning of 2026, achieving a "five consecutive days of gains" with a peak single-day trading volume of 15.45 million shares, the highest since October of the previous year [1] Group 2: Financial Performance - In the 2025 mid-year report, the company reported revenues of USD 278 million, a year-on-year decrease of 9.2%. However, due to the sale of non-core joint venture equity, net profit surged to USD 455 million, a 16.6-fold increase [2] - The sales of the company's three main innovative drugs, including Fuzulopatinib, Surufatinib, and Savolitinib, saw a significant decline of 30-50%, leading to a 22% year-on-year drop in self-owned product sales [2] Group 3: Market Sentiment and Trading Behavior - Following the mid-year report, the stock price underwent a month-long adjustment, with a brief recovery in mid-September, but this was interrupted by a decline in the Hang Seng Healthcare Index [3] - The stock exhibited a "follow the market down" behavior, with a shift in trading style among investors, particularly in the Hong Kong Stock Connect, which began to align more closely with the stock's price movements starting in November [5] Group 4: Pipeline and Future Prospects - The decline in stock performance in 2025 was attributed to the lack of commercial performance from the main innovative drugs, creating a gap in the second half of the year [7] - The company has developed a diversified pipeline from oncology to autoimmune diseases, with several candidates entering critical clinical stages, including Sovleplenib, HMPL-453, HMPL-306, and HMPL-506 [7] - Recent updates on the progress of new and existing pipeline products have driven the stock's rebound, with significant announcements regarding new drug applications and clinical trial advancements [8][9] Group 5: Specific Drug Developments - Sovleplenib, a selective oral SYK inhibitor, is expected to be approved this year for the treatment of refractory/relapsed primary immune thrombocytopenia (ITP), potentially generating new revenue streams [9] - HMPL-453, a selective and potent FGFR1/2/3 inhibitor, is anticipated to be approved by 2027, indicating a long-term growth potential for the company [10]

Core Insights - The biopharmaceutical industry is at a pivotal moment as it transitions from the "14th Five-Year Plan" to the "15th Five-Year Plan," emphasizing the balance between technological innovation and value-driven growth [1] - The recent surge in the innovative drug sector, with the Shanghai Composite Index achieving a 14-day winning streak and the Hong Kong innovative drug index rising by an average of 12% over three days, indicates strong market support for innovative pharmaceuticals [4] - The Chinese government has reinforced its commitment to the innovative drug sector through policies like "Full Chain Support for Innovative Drug Development," which is expected to create significant industry opportunities [4] Industry Growth Drivers - Innovative drugs are recognized as a critical new productive force, comparable in priority to AI and other emerging technologies, with substantial government backing [4] - In 2025, China signed over 150 new business development (BD) agreements in the innovative drug sector, totaling more than $130 billion, a 150% increase from 2024, with upfront payments reaching $7 billion [5] - The anticipated "milestone" rewards from these agreements could exceed $30 billion in the next 3-5 years, fostering the growth of China's innovative drug market despite inherent development risks [5] Market Dynamics - The global biopharmaceutical development landscape is revitalizing due to expiring drug patents and a favorable interest rate environment, with major pharmaceutical companies increasing their R&D investments [6] - The emergence of blockbuster innovative drugs in China, such as AK112 and SKB264, showcases the potential for significant sales in the global market, with some products challenging established leaders [6][7] - The international geopolitical climate is expected to enhance China's economic prospects, leading to increased capital inflows into A-shares and Hong Kong stocks, signaling the onset of a major bull market [7] Future Outlook - The period between 2026 and 2027 is anticipated to yield significant clinical breakthroughs in innovative drugs, potentially leading to substantial stock price revaluations [7] - The next 20 years are projected to be a prosperous era for China, with substantial returns expected for those following technological innovations in the biopharmaceutical sector [8]

Group 1: Overseas Service Industry - The investment rating for the overseas service industry is positive, with Macau's gaming revenue maintaining double-digit growth and visitor numbers reaching historical highs [1][3]. - In December, Macau's gross gaming revenue was 20.9 billion MOP, representing a year-on-year increase of 14.8%, and recovering to 91% compared to the same period in 2019 [3]. - The total number of visitors to Macau in 2025 is projected to be 40.06 million, a year-on-year increase of 14.7%, marking a historical high [3]. Group 2: Overseas Pharmaceutical Industry - The investment rating for the overseas pharmaceutical industry is optimistic, with significant advancements in drug approvals and clinical trials [2][6]. - BeiGene's BCL2 inhibitor received conditional approval in China for treating chronic lymphocytic leukemia and mantle cell lymphoma, marking it as the first approved BCL2 inhibitor for MCL in the country [6][7]. - The Hang Seng Healthcare Index rose by 11.15%, outperforming the Hang Seng Index by 9.12 percentage points [6]. Group 3: Overseas Education Industry - The investment rating for the overseas education industry is favorable, with a focus on vocational training and spring enrollment [12][14]. - The education index increased by 2.7% in the first week of January, outperforming the Hang Seng National Enterprises Index by 1.3 percentage points [12]. - China Oriental Education is recommended as a top pick due to its proactive operational adjustments and expected enrollment growth in the second half of the year [14].

Market Performance - The A-share market showed significant strength with the Shanghai Composite Index rising by 0.92%, surpassing 4100 points, marking a new high in over 10 years [1] - For the week, the Shanghai Composite Index increased by 3.82%, the Shenzhen Component Index by 4.4%, and the ChiNext Index by 3.89% [1] Trading Volume - The total market turnover exceeded 3.15 trillion yuan, an increase of 326.1 billion yuan from the previous trading day, marking the sixth occurrence in history where turnover surpassed 3 trillion yuan [3] - Over 3900 stocks in the market experienced gains [3] AI Sector - The AI application sector saw a collective surge, with concepts like Xiaohongshu leading the gains, followed by Sora and Kuaishou [3][7] - The AI application sector is expected to enter a "golden year" in 2026, driven by technological maturity, supportive policies, and market demand [10][11] Notable Stocks - Zhite New Materials became the first stock to double in 2026, with a price increase of over 148% from January 5 to January 9, achieving five consecutive "20CM" limit-ups [3][4] - The stock is associated with AI-driven scientific research, new materials, robotics, and quantum technology [4][5] Innovation Drug Sector - The innovative drug sector experienced a strong rally, with companies like Weikang Pharmaceutical and Qianyan Bio hitting the "20CM" limit-up [13] - The National Medical Products Administration is optimizing the approval process for urgently needed foreign drugs, which is expected to support the innovative drug sector's growth [16][17]

Group 1 - Fitch expects the Federal Reserve to cut interest rates twice in the first half of 2026, with the unemployment rate stabilizing at 4.6% [1] - Goldman Sachs reports that investor sentiment towards oil is at its most pessimistic level in nearly a decade, with over 59% of surveyed institutional investors bearish on the oil market [2] - Goldman Sachs forecasts a robust global economic growth of 2.8% in 2026, surpassing the market expectation of 2.6%, driven by a strong performance in the US and China [3] Group 2 - Guggenheim indicates that the market has largely absorbed geopolitical risks but remains cautious about headline risks that could impact stock market resilience [4] - UOB raises its gold price forecast due to increased demand for safe-haven assets amid rising geopolitical risks, projecting gold prices to reach $5,000 per ounce by Q4 2026 [5] - CICC anticipates a short-term supply gap in the wood chip market in 2026, leading to a potential increase in pulp prices as demand improves [6] Group 3 - Tianfeng Securities is optimistic about A-share gaming companies entering a strong product cycle in 2026, driven by improved competition and stable regulatory environments [7] - CITIC Securities expects an expansion in the issuance of local government bonds in 2026, with a focus on matching issuance pace with market conditions [8] - CITIC Securities predicts that the Hang Seng Index will undergo adjustments, with 38 stocks expected to enter the Hong Kong Stock Connect [9] Group 4 - CITIC Securities highlights the potential for increased domestic tourism revenue in 2026, estimating an annual increment of 500 to 1,650 billion yuan due to new policies promoting worker consumption [10] - CITIC Jian Investment identifies a bottoming opportunity in the liquor sector, suggesting that the current adjustment phase may soon reverse as market expectations improve [11] - Huatai Securities sees a recovery in the innovative drug sector in Hong Kong, driven by liquidity restoration and multiple catalysts expected in the upcoming year [12]

Market Overview - The A-share market rose again on January 9, with the Shanghai Composite Index breaking through 4100 points, marking a continuous 16-day increase [1] - The total trading volume of the entire A-share market exceeded 3 trillion yuan, the first time since October 2025 [1] - The Shanghai Composite Index closed up 0.92% at 4120.43 points, while the Shenzhen Component Index rose 1.15% and the ChiNext Index increased by 0.77% [1] AI Application Concept - The AI application concept saw a significant surge, with stocks like Yidian Tianxia and Kunlun Wanwei hitting the 20% limit up, and Xinghuan Technology reaching a historical high [3][5] - The Ministry of Industry and Information Technology and other departments issued an implementation opinion for the "Artificial Intelligence + Manufacturing" initiative, aiming for key AI technologies to achieve reliable supply by 2027 [5] - The proportion of industrial enterprises applying large models and intelligent agents in China is expected to rise from 9.6% in September 2024 to 47.5% by 2025, driven by policy support [5] Military Industry Sector - The military sector showed strong performance, with stocks like Qian Zhao Guangdian and Zhenyou Technology hitting the 20% limit up, and companies like Zhenlei Technology and China Satellite Communications reaching historical highs [7][9] - According to a report, 2025 is expected to be a turning point for the military industry, with a rebound in revenue and profit expected [9] - The military trade market is anticipated to experience historical opportunities due to a shift from "cost-effective alternatives" to "technical benchmarks" in recent years [9] Notable Stocks - Fenglong Co. continued its upward trend, achieving an 11-day consecutive limit up, while Lushin Investment also saw a significant increase with 9 limit ups in 11 trading days [11][12] - Zhi Te New Materials experienced a 150% increase over five consecutive trading days, although it warned of potential risks due to significant price deviations from market trends [13]

Market Overview - The A-share market showed significant strength with the Shanghai Composite Index rising by 0.92%, surpassing 4100 points, marking a new high in over 10 years [2] - The Shanghai Composite Index accumulated a weekly increase of 3.82%, while the Shenzhen Component Index and the ChiNext Index rose by 4.4% and 3.89%, respectively [2] Trading Volume and Stock Performance - The total market turnover exceeded 3.15 trillion yuan, an increase of 326.1 billion yuan from the previous trading day, marking the sixth occurrence in history of turnover exceeding 3 trillion yuan [4] - Over 3900 stocks in the market experienced gains, with notable performances in AI application sectors, particularly the Xiaohongshu concept leading the gains [4][5] AI Sector Developments - The AI application sector saw a collective surge, with stocks like Tianlong Group and Yidian Tianxia hitting the daily limit of 20% [5] - Zhite New Materials emerged as the first stock to double in 2026, with a price increase of over 148% from January 5 to January 9, 2026 [4] - Zhite New Materials integrates popular concepts such as AI-driven scientific research, new materials, robotics, and quantum technology [4] Future Outlook for AI Applications - Analysts predict that 2026 will be a "golden year" for AI applications, driven by technological maturity, supportive policies, and market demand [8] - The global creative application market is expected to reach $54.6 billion by 2027, with an anticipated penetration rate of 11% for AI creative applications [8] Pharmaceutical Sector Insights - The innovative drug sector experienced a strong rally, with companies like Weikang Pharmaceutical and Qianyan Biology hitting the daily limit of 20% [10] - The National Medical Products Administration emphasized support for the pharmaceutical industry, aiming to enhance quality and efficiency in 2026 [12] - The new basic medical insurance directory and the first version of the commercial insurance innovative drug directory were implemented nationwide, adding 114 new drugs to the basic insurance directory [12] Long-term Projections for Pharmaceuticals - Analysts believe that the innovative drug sector will dominate the pharmaceutical industry in China, with the integration of basic and commercial insurance opening up long-term payment space for innovative drugs [13]

Group 1: Overseas Social Services - The investment rating for the overseas social services sector is positive, with a focus on Macau's gaming revenue maintaining double-digit growth and record visitor numbers during New Year's [1][4]. - In December, Macau's gross gaming revenue reached 20.9 billion MOP, representing a year-on-year increase of 14.8%, and recovering to 91% compared to the same period in 2019. The total gross gaming revenue is expected to grow by 9.1% in 2025 [4]. - The total number of visitors to Macau in 2025 is projected to be 40.06 million, a year-on-year increase of 14.7%, marking a historical high. On New Year's Day 2026, the number of visitors reached 188,000, the highest ever for that day [4]. Group 2: Overseas Pharmaceuticals - The investment rating for the overseas pharmaceuticals sector is also positive, with significant developments in drug approvals and clinical trials [2][7]. - BeiGene's BCL2 inhibitor received conditional approval in China for treating chronic lymphocytic leukemia and mantle cell lymphoma, marking it as the first and only BCL2 inhibitor approved for MCL in the country [8][9]. - The Hang Seng Healthcare Index rose by 11.15%, outperforming the Hang Seng Index by 9.12 percentage points, indicating strong market performance [7]. Group 3: Overseas Education - The investment rating for the overseas education sector is favorable, with a focus on vocational education and training [3][14]. - The education index increased by 2.7%, outperforming the Hang Seng Index by 1.3 percentage points, indicating a positive market trend [14]. - The report suggests focusing on Hong Kong vocational education companies, particularly China Oriental Education, which is expected to see enrollment growth due to strategic adjustments in response to market demand [16].

Investment Rating - The report gives a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26][32]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 3.61% from December 26, 2025, to January 8, 2026, exceeding the CSI 300 index by approximately 1.56 percentage points [12]. - Most sub-sectors within the industry recorded positive returns during the same period, with the hospital and medical R&D outsourcing sectors leading with increases of 10.62% and 7.39%, respectively [13]. - Approximately 82% of stocks in the industry achieved positive returns, with notable performers including Xiangyu Medical, which saw a weekly increase of 57.50% [14][17]. - The overall industry valuation has risen, with the SW pharmaceutical and biotechnology index's PE (TTM) at approximately 52.75 times, which is 3.78 times higher than the CSI 300 index [18][26]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 3.61% from December 26, 2025, to January 8, 2026 [12]. - Most sub-sectors recorded positive returns, particularly hospitals and medical R&D outsourcing, which increased by 10.62% and 7.39%, respectively [13]. - About 82% of stocks in the industry had positive returns, with significant gains from several companies [14]. 2. Industry News - The report highlights the acceleration of volume-based procurement in 2026, with various local and national initiatives underway to streamline drug procurement processes [24]. - A new batch of encouraged generic drugs has been announced, focusing on optimizing the drug supply system and enhancing the availability of essential medications [23]. 3. Company Announcements - Jiangsu Yahui Pharmaceutical announced the completion of the first patient enrollment in a Phase I clinical trial for its drug APL-2401, targeting advanced solid tumors [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, particularly following announcements from Neuralink regarding large-scale production plans [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28][29].